Technology | 2010.03.02
Advanced Cell Technology's RPE Cells Granted Orphan Drug Status from FDA for Treatment of Stargardt’s Macular Dystrophy
WORCESTER, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTCBB: ACTC), a biotechnology company applying cellular technology in the field of regenerative medicine, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company’s MA09-hRPE cells for use in the treatment of Stargardt’s Macular Dystrophy (SMD). As a result, the company is eligible to receive a number of benefits, including tax credits, access to grant f
For more information, please visit
http://www.businesswire.com/news/home/20100302006136/en
